Trial Profile
Study of the safety, tolerability, pharmacokinetics and immunogenicity of REGN-668 administered subcutaneously to healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2012
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Adverse reactions
- 12 Mar 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2011 New trial record